Compare CAI & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAI | CORT |
|---|---|---|
| Founded | 2008 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 9.7B |
| IPO Year | 2025 | 2001 |
| Metric | CAI | CORT |
|---|---|---|
| Price | $23.05 | $72.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 5 |
| Target Price | $34.23 | ★ $142.60 |
| AVG Volume (30 Days) | ★ 3.8M | 1.2M |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.79 | N/A |
| EPS | 0.05 | ★ 1.13 |
| Revenue | ★ $812,033,000.00 | $761,407,000.00 |
| Revenue This Year | $28.81 | $52.09 |
| Revenue Next Year | $19.11 | $44.73 |
| P/E Ratio | $477.70 | ★ $65.17 |
| Revenue Growth | ★ 96.97 | 12.79 |
| 52 Week Low | $14.19 | $28.66 |
| 52 Week High | $36.50 | $126.38 |
| Indicator | CAI | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 31.26 | 26.07 |
| Support Level | $21.99 | $30.24 |
| Resistance Level | $23.66 | $122.93 |
| Average True Range (ATR) | 2.05 | 4.53 |
| MACD | -1.17 | -0.39 |
| Stochastic Oscillator | 3.45 | 13.82 |
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.